Clinical Trials Logo

Clinical Trial Summary

To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01696084
Study type Interventional
Source Jazz Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date December 13, 2012
Completion date December 31, 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05066958 - Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT Phase 1/Phase 2
Recruiting NCT05237258 - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia N/A
Recruiting NCT06394011 - Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients Phase 2
Active, not recruiting NCT02861417 - Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Phase 2
Recruiting NCT03384212 - CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML Phase 3
Recruiting NCT03384225 - CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML Phase 3